10-QPeriod: Q2 FY2023

GE HealthCare Technologies Inc. Quarterly Report for Q2 Ended Jun 30, 2023

Filed July 25, 2023For Securities:GEHC

Summary

GE HealthCare Technologies Inc. reported solid top-line growth in its second quarter of 2023, with total revenues increasing by 7% year-over-year to $4.8 billion, and 9% on an organic basis. This growth was driven by strong performance across all segments, particularly Pharmaceutical Diagnostics (PDx) and Imaging. The company also saw continued improvements in supply chain fulfillment and benefits from price increases. Despite revenue growth, net income attributable to GE HealthCare decreased by 14% to $418 million, primarily impacted by higher interest expenses related to new debt issuances and the drawn Term Loan Facility, as well as increased operating expenses related to the company's transition to a standalone entity. The company also highlighted ongoing investments in R&D and commercial initiatives. GE HealthCare maintained a strong balance sheet with $1.9 billion in cash and cash equivalents and access to significant credit facilities, indicating financial stability. The company reiterated its full-year outlook, underscoring its confidence in continued growth and operational execution.

Financial Highlights

51 data points
Beta

Revenue

$4.82B

40.3% Gross Margin

Net Income

$418.00M

8.7% Net Margin

EPS (Diluted)

$0.91

Total Assets

$32.31B

Cash & Equivalents

$1.95B

Free Cash Flow

-$137.00M

Financial Statements
Beta
Revenue$4.82B
Gross Profit$1.94B
R&D Expenses$298.00M
SG&A Expenses$1.07B
Operating Expenses$1.37B
Operating Income$570.00M
Net Income$418.00M
EPS (Basic)$0.92
EPS (Diluted)$0.91
Shares Outstanding (Basic)455.00M
Shares Outstanding (Diluted)458.00M

Key Highlights

  • 1Total revenues increased 7% to $4.8 billion, with 9% organic growth, reflecting broad-based segment performance.
  • 2Pharmaceutical Diagnostics (PDx) and Imaging segments showed particularly strong revenue growth, up 19% and 7% respectively.
  • 3Net income attributable to GE HealthCare declined 14% to $418 million, impacted by increased interest expenses and operating costs related to the spin-off.
  • 4Operating income decreased by 10% year-over-year, with margins compressed due to higher operating expenses and cost inflation, partially offset by pricing actions and cost productivity.
  • 5The company ended the quarter with a healthy cash position of $1.9 billion, supported by $3.5 billion in available credit facilities.
  • 6Remaining Performance Obligations (RPO) remained stable at $14.3 billion, indicating a solid backlog of future revenue.

Frequently Asked Questions

The primary driver of revenue growth was a combination of strong demand across all segments, improved supply chain fulfillment, and the impact of price increases. The Pharmaceutical Diagnostics (PDx) and Imaging segments, in particular, showed significant revenue increases.

The decrease in net income was primarily due to higher interest expenses associated with recent debt issuances and the Term Loan Facility, as well as increased operating expenses related to the company's transition to a standalone entity and planned investments in R&D and commercial activities.

GE HealthCare maintains a strong financial position, ending the quarter with $1.9 billion in cash and cash equivalents. The company also has access to $3.5 billion in revolving credit facilities, providing ample liquidity to meet its operational needs and financial commitments.

The Remaining Performance Obligations (RPO) remained stable at $14.3 billion as of June 30, 2023. This indicates a substantial backlog of contracted revenue, with product-related RPO expected to be recognized within two years and service-related RPO within five years, providing visibility into future revenue streams.